MRNA (Moderna) Short Interest


MRNA Moderna Inc MRNA
60 GF Score
Price $60.42
GF Value $22.94
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Moderna Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MRNA vs INCY, ROIV, JAZZ: Short Interest Comparison

For the Biotechnology subindustry, Moderna's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Short Interest distribution charts can be found below:

* The bar in red indicates where Moderna's Short Interest falls into.


MRNA
60GF Score
Moderna Inc MRNA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Moderna (MRNA) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of $60.42 is trading 163.4% above its estimated GF Value™ of $22.94. GuruFocus considers Moderna to be Significantly Overvalued.

Key valuation signals for MRNA:

  • Short Interest:
  • GF Value™: $22.94 vs. price of $60.42 (163.4% above fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the MRNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
60GF Score

Get the complete analysis for MRNA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$60.42
Price
$22.94
GF Value